CST, 83643T, CSF-1R/M-CSF-R (F1H1I) Rabbit Monoclonal Antibody

Monoclonal Antibody for studying CSF1R mouse. Validated for Western Blotting,Immunohistochemistry (Paraffin). Available in 2 sizes. Highly specific and rigorously validated in-house, CSF-1R/M-CSF-R (F1H1I) Rabbit Monoclonal Antibody (CST #83643) is ready to ship. Product Usage Information Western Blotting: 1:1000 Immunohistochemistry (Paraffin): 1:200 - 1:800 Storage Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/mL BSA, 50% glycerol, and less than 0.02% sodium azide. Store at -20°C. Do not aliquot the antibody. Protocol Available protocols: Western Blotting, Immunohistochemistry (Paraffin) Specificity / Sensitivity CSF-1R/M-CSF-R (F1H1I) Rabbit Monoclonal Antibody recognizes endogenous levels of total CSF-1R/M-CSF-R protein. Species Reactivity: Mouse, Rat Source / Purification Monoclonal antibody is produced by immunizing animals with a recombinant protein specific to the carboxy terminus of mouse CSF-1R/M-CSF-R protein. This antibody recognizes residues surrounding Val722 of mouse CSF-1R/M-CSF-R protein. Background Macrophage-colony stimulating factor (M-CSF, CSF-1) receptor is an integral membrane tyrosine kinase encoded by the proto-oncogene. M-CSF receptor is expressed in monocytes (macrophages and their progenitors) and drives growth and development of this blood cell lineage (1-3). Binding of M-CSF to its receptor induces receptor dimerization, activation, and autophosphorylation of cytoplasmic tyrosine residues used as docking sites for SH2-containing signaling proteins (4). There are at least five major tyrosine autophosphorylation sites. Tyr723 (Tyr721 in mouse) is located in the kinase insert (KI) region. Phosphorylated Tyr723 binds the p85 subunit of PI3 kinase as well as PLCγ2 (5). Phosphorylation of Tyr809 provides a docking site for Shc (5). Overactivation of this receptor can lead to a malignant phenotype in various cell systems (6). The activated M-CSF receptor has been shown to be a predictor of poor outcome in advanced epithelial ovarian carcinoma (7) and breast cancer (8). After initial dimerization and autophosphorylation, the CSF-1 receptor undergoes regulated intramembrane proteolysis (RIP) that involves proteolytic processing of this membrane protein and results in release of extracellular domain, intramembrane cleavage and release of the cytoplasmic domain into the cytosol (9). The activated intracellular domain then moves to the nucleus and regulates transcription of specific genes (10). It has been shown that the processing and down modulation of CSF-1 receptor is a continuous process and its rate increases substantially in response to a variety of stimuli, including PMA, LPS, tumor necrosis factor, IL-2, Il-4, and its physiological ligand CSF-1 (9). Alternate Names AI323359; c-fms; CD115; colony stimulating factor 1 receptor; Csf; CSF-; CSF-1 receptor; CSF-1-R; CSF-1R; Csf1r; Csfmr; CSFR; Fim; Fim-; Fim-2; Fim2; Fms; M-CS; M-CSF-R; M-CSFR; Macrophage colony-stimulating factor 1 receptor; OTTMUSP00000015851; Proto-oncogene c-Fms; proto-oncogene fms Specification REACTIVITY: M R SENSITIVITY: Endogenous MW (kDa): 52 cytoplasmic domain. 140 precursor. 175 M-CSF Receptor. Source/Isotype: Rabbit IgG